NanoenTekInc
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a resid… Read more
NanoenTekInc (039860) - Total Liabilities
Latest total liabilities as of September 2025: ₩5.42 Billion KRW
Based on the latest financial reports, NanoenTekInc (039860) has total liabilities worth ₩5.42 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NanoenTekInc - Total Liabilities Trend (2007–2024)
This chart illustrates how NanoenTekInc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NanoenTekInc Competitors by Total Liabilities
The table below lists competitors of NanoenTekInc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FFD Financial Corp
PINK:FFDF
|
USA | $719.90 Million |
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩50.75 Billion |
|
TOLUF
OTCQX:TOLUF
|
USA | $9.82 Million |
|
Nexen Corporation
KO:005720
|
Korea | ₩3.26 Trillion |
|
Dusit Thani Public Company Limited
BK:DUSIT
|
Thailand | ฿30.70 Billion |
|
Kenilworth Systems C
PINK:KENS
|
USA | $7.44 Million |
|
Alpha Cognition Inc
NASDAQ:ACOG
|
USA | $12.39 Million |
|
Cardiol Therapeutics Inc Class A
NASDAQ:CRDL
|
USA | $3.39 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down NanoenTekInc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoenTekInc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoenTekInc (2007–2024)
The table below shows the annual total liabilities of NanoenTekInc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩5.01 Billion | +0.54% |
| 2023-12-31 | ₩4.99 Billion | -11.42% |
| 2022-12-31 | ₩5.63 Billion | -44.35% |
| 2021-12-31 | ₩10.11 Billion | +38.01% |
| 2020-12-31 | ₩7.33 Billion | +30.55% |
| 2019-12-31 | ₩5.61 Billion | -19.93% |
| 2018-12-31 | ₩7.01 Billion | -62.38% |
| 2017-12-31 | ₩18.64 Billion | -7.41% |
| 2016-12-31 | ₩20.13 Billion | +40.99% |
| 2015-12-31 | ₩14.28 Billion | +84.03% |
| 2014-12-31 | ₩7.76 Billion | -63.45% |
| 2013-12-31 | ₩21.23 Billion | -1.09% |
| 2012-12-31 | ₩21.46 Billion | +2.68% |
| 2011-12-31 | ₩20.90 Billion | +193.93% |
| 2007-12-31 | ₩7.11 Billion | -- |